• Kaushal Y. Pathak Clinical Research Department, Torrent Pharmaceuticals Limited, Village- Bhat, Dist. Gandhinagar, India
  • Anookh Mohanan
  • Shivani Acharya
  • Divyesh Mandavia
  • Hemant R. Jadhav


Cardiometabolic risk, Magnetic resonance imaging, Receiver operating curve


Objective: Visceral adiposity index (VAI) is a simple clinical algorithm developed as a surrogate marker for characterizing visceral adiposity dysfunction (VAD). This study aimed to explore an optimal VAI cut off value for predicting VAD as reflected quantitatively by magnetic resonance imaging (MRI) and to evaluate its merit in predicting the severity of the cardiometabolic risk (CMR) in type 2 diabetic patients of India.

Methods: Data was collected from 81 diabetics and 48 healthy participants, who underwent metabolic assessments. VAI derived using BMI, waist circumference (WC), triglycerides (TG) and HDLc, was studied against visceral fat area measuring ≥130 cm2 by MRI as it is associated with higher CMR through raised VAD. Optimal VAI cutoff was determined using the area under the receiver operator characteristic curve (AUROC). Diabetic participants were divided into VAD absent, and VAD present groups based on derived VAI cut off to study associated difference in their metabolic profile.

Results: Diabetic group had significantly deranged metabolic profile compared to the healthy control group. Most of the diabetic group participants had a visceral fat area between 101 and 200 cm2. From the ROC curve analysis (AUROC = 0.761), VAI cut-off of 2.0 predicted VAD with sensitivity and specificity of 73.21% and 71.23% respectively. Diabetic participants with VAI values more than 2, had significantly (p<0.05) higher WC, visceral fat, fasting insulin, HOMA-IR (Homeostatic model assessment for insulin resistance), TG (p<0.01), non-HDLc and apolipoprotein B/A1 ratio values. Age adjusted partial correlation analysis showed a significant (p<0.01) positive correlation between VAI and HOMA-IR.

Conclusion: VAI was useful in predicting VAD and identifying the severity of CMR within type 2 diabetics. VAI can replace imaging procedures with the advantages of reduced economic burden and can be used as screening tool for surveillance of CMR in Indian population. 


Download data is not yet available.


Despres JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006;38:52-63.

Gerich JE. Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. Clin Cornerstone 2007;8:53-68.

Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 2002;87:5098-103.

Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012;126:1301-13.

Joshi SR. Type 2 diabetes in Asian Indians. Clin Lab Med 2012;32:207-16.

Nicklas BJ, Penninx BW, Ryan AS, Berman DM, Lynch NA, Dennis KE. Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care 2003;26:1413-20.

Oh JY, Sung YA, Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity (Silver Spring) 2013;21:1690-4.

Klopfenstein BJ, Kim MS, Krisky CM, Szumowski J, Rooney WD, Purnell JQ. Comparison of 3 T MRI and CT for the measurement of visceral and subcutaneous adipose tissue in humans. Br J Radiol 2012;85:e826-30.

Hunter GR, Snyder SW, Kekes-Szabo T, Nicholson C, Berland L. Intra-abdominal adipose tissue values associated with risk of possessing elevated blood lipids and blood pressure. Obes Res 1994;2:563-8.

Hunter GR, Gower BA, Kane BL. Age related shift in visceral fat. Int J Body Composition Res 2010;8:103-8.

Rankinen T, Kim SY, Perusse L, Despres JP, Bouchard C. The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. Int J Obes Related Metab Disorders 1999;23:801-9.

Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a caucasian sicilian population. Lipids Health Dis 2011;10:183.

Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010;33:920-2.

Amato MC, Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol 2014. Doi.org/10.1155/2014/730827.

Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One 2014;9:e91969. Doi:10.1371/journal.pone.0091969.

Kumpatla S, Michael C, Viswanathan V. Visceral adiposity index and pattern of dyslipidaemia at different stages of glucose intolerance-a study from India. Diabetes Metab Syndrome: Clin Res Rev 2011;5:173-8.

Han L, Fu KL, Zhao J, Wang ZH, Tang MX, Wang J, et al. Visceral adiposity index score indicated the severity of coronary heart disease in Chinese adults. Diabetol Metab Syndr 2014;6:1-6.

Poulsen MK, Henriksen JE, Vach W, Dahl J, Moller JE, Johansen A, et al. Identification of asymptomatic type 2 diabetes mellitus patients with a low, intermediate and high risk of ischaemic heart disease: is there an algorithm? Diabetologia 2010;53:659-67.

Anitha M. Prevalence of obesity and overweight among medicos in both male and female students. Asian J Pharm Clin Res 2016;26:289-91.



How to Cite

Pathak, K. Y., A. Mohanan, S. Acharya, D. Mandavia, and H. R. Jadhav. “EXPLORING VISCERAL ADIPOSITY INDEX AS A PREDICTOR OF VISCERAL ADIPOSITY DYSFUNCTION AND EVALUATING ITS PERFORMANCE IN PREDICTING HEPATIC INSULIN RESISTANCE IN INDIAN TYPE 2 DIABETICS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 8, Aug. 2016, pp. 297-01, https://innovareacademics.in/journals/index.php/ijpps/article/view/12593.



Original Article(s)